Drug interactions
Metformin-pioglitazone + Ponatinib
Severity: Minor
Metformin-pioglitazone and Ponatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponatinib labeling mentions OATP1B1 inhibitors as raising myopathy risk, but pioglitazone is not an established clinically relevant OATP1B1 inhibitor. The interaction is theoretical and the clinical significance is unclear. Ponatinib itself can cause hyperglycemia, which may affect diabetes control.
What this interaction means in plain words
Metformin-pioglitazone and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Metformin-pioglitazone belongs to Endocrine; Ponatinib belongs to Oncology.
Why it happens
Possible weak OATP1B1 inhibition by pioglitazone; mechanism not established.
What to do
No dose adjustment is required. Monitor blood glucose and report muscle pain or weakness.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Metformin-pioglitazone and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-pioglitazone
Other interactions of Ponatinib
Frequently asked questions
Can I take Metformin-pioglitazone with Ponatinib?
MediHelp rates the interaction as minor. Metformin-pioglitazone and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Ponatinib labeling mentions OATP1B1 inhibitors as raising myopathy risk, but pioglitazone is not an established clinically relevant OATP1B1 inhibitor. The interaction is theoretical and the clinical significance is unclear. Ponatinib itself can cause hyperglycemia, which may affect diabetes control.
How serious is the interaction between Metformin-pioglitazone and Ponatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is required. Monitor blood glucose and report muscle pain or weakness.
What other medicines interact with Metformin-pioglitazone?
MediHelp also lists interactions of Metformin-pioglitazone with, for example, Contrast media, Diatrizoate meglumine / diatrizoate, Diatrizoate. The full list is on the Metformin-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
